Vivo Bio Tech . Falls to 52-Week Low of Rs.30.99 Amidst Continued Downtrend

Trading below all key moving averages—including the 5-day, 20-day, 50-day, 100-day, and 200-day—Vivo Bio Tech . is exhibiting a persistent weakness in price momentum. This contrasts with the broader market, where the Sensex advanced by 0.4% to close at 85,010.04, just 0.33% shy of its 52-week high of 85,290.06. The Sensex’s positive trajectory was supported by mega-cap stocks and bullish moving average alignments, highlighting a divergence between Vivo Bio Tech . and the overall market trend.

Over the last year, Vivo Bio Tech . has generated a return of -21.59%, significantly lagging behind the Sensex’s 9.58% gain. The stock’s 52-week high was Rs.56.90, underscoring the extent of the recent decline. This underperformance extends beyond the last year, with the stock consistently trailing the BSE500 index across the past three annual periods.

Examining the company’s financial metrics reveals several factors contributing to the current valuation pressures. Vivo Bio Tech . has exhibited a compound annual growth rate (CAGR) of -0.92% in net sales over the past five years, indicating a contraction in revenue generation. The company’s ability to service its debt is reflected in an average EBIT to interest ratio of 1.95, which suggests limited coverage of interest expenses by operating earnings.

Profitability metrics also point to challenges, with an average return on equity (ROE) of 7.49%, signalling modest returns on shareholders’ funds. The company’s return on capital employed (ROCE) stands at 9.3%, which, while modest, is accompanied by an enterprise value to capital employed ratio of 0.9, indicating a valuation discount relative to capital base.

Despite the subdued price performance, some recent operational data show pockets of improvement. The latest quarterly net sales reached Rs.12.51 crores, the highest recorded for the company in recent periods. Additionally, the operating profit to interest coverage ratio for the quarter was 3.65 times, the highest in recent quarters, suggesting a temporary easing in financial strain. The profit after tax (PAT) for the latest six months was Rs.2.40 crores, reflecting a growth rate of 163.74% compared to the previous corresponding period.

However, these positive developments have not translated into sustained price recovery, as the stock continues to trade at a discount compared to its peers’ average historical valuations. Over the past year, while profits have declined by 42.5%, the stock’s price has fallen by 21.59%, indicating a disconnect between earnings contraction and share price movement.

Ownership structure indicates that majority shareholders are non-institutional investors, which may influence liquidity and trading patterns. The stock’s Mojo Score currently stands at 32.0, with a Mojo Grade of Sell as of 8 August 2025, reflecting an adjustment in evaluation from a previous Strong Sell grade. This revision aligns with the stock’s recent price movements and financial performance metrics.

In summary, Vivo Bio Tech .’s fall to a 52-week low of Rs.30.99 is underpinned by a combination of subdued revenue growth, constrained profitability, and limited debt servicing capacity. While recent quarterly figures show some improvement in sales and profit after tax, the stock remains below all major moving averages and continues to underperform its sector and benchmark indices. The broader market environment remains positive, with the Sensex near its 52-week high, highlighting the stock’s relative weakness within the Pharmaceuticals & Biotechnology sector.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →